- Home
- HMST vs ACIU Comparison
HMST vs ACIU Comparison
Compare HMST & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- ACIU
- Stock Information
- Founded
- HMST 1921
- ACIU 2003
- Country
- HMST United States
- ACIU Switzerland
- Employees
- HMST N/A
- ACIU N/A
- Industry
- HMST Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- ACIU Health Care
- Exchange
- HMST Nasdaq
- ACIU Nasdaq
- Market Cap
- HMST 287.6M
- ACIU 305.7M
- IPO Year
- HMST 2012
- ACIU 2016
- Fundamental
- Price
- HMST $11.29
- ACIU $3.29
- Analyst Decision
- HMST Buy
- ACIU Strong Buy
- Analyst Count
- HMST 2
- ACIU 2
- Target Price
- HMST $13.25
- ACIU $12.00
- AVG Volume (30 Days)
- HMST 245.4K
- ACIU 130.5K
- Earning Date
- HMST 10-29-2024
- ACIU 11-05-2024
- Dividend Yield
- HMST 3.46%
- ACIU N/A
- EPS Growth
- HMST N/A
- ACIU N/A
- EPS
- HMST N/A
- ACIU N/A
- Revenue
- HMST $169,710,000.00
- ACIU $48,505,404.00
- Revenue This Year
- HMST N/A
- ACIU N/A
- Revenue Next Year
- HMST $10.09
- ACIU $938.44
- P/E Ratio
- HMST N/A
- ACIU N/A
- Revenue Growth
- HMST N/A
- ACIU 4097200.00
- 52 Week Low
- HMST $5.98
- ACIU $2.25
- 52 Week High
- HMST $16.10
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- HMST 42.00
- ACIU 53.10
- Support Level
- HMST $10.52
- ACIU $3.11
- Resistance Level
- HMST $11.80
- ACIU $3.41
- Average True Range (ATR)
- HMST 0.60
- ACIU 0.24
- MACD
- HMST 0.18
- ACIU 0.03
- Stochastic Oscillator
- HMST 80.59
- ACIU 40.40
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.